Is orencia available as a self injectable pen?

Is Orencia available as a self-injectable pen?

Orencia is available as a prefilled autoinjector pen that patients can use themselves after proper training. The pen delivers 125 mg of abatacept once weekly for subcutaneous use in adults with rheumatoid arthritis or psoriatic arthritis.

How does the Orencia pen compare with the prefilled syringe?
Both the pen and syringe contain the same dose and formulation. The pen has a hidden needle and button activation, which some patients find easier and less intimidating than manually inserting the syringe needle.

When should patients choose the pen versus the syringe?
Patients who prefer a one-button, spring-loaded device often choose the pen. Those comfortable with manual injection or who need to control insertion speed may stay with the syringe. Insurance coverage and pharmacy stock can also influence the choice.

Who makes the Orencia autoinjector pen?
Bristol Myers Squibb manufactures both the pen and syringe versions. No authorized generic or biosimilar autoinjector is currently marketed in the United States.

When does the Orencia patent expire?
Key U.S. patents covering the subcutaneous formulation and pen device extend into the late 2020s. Biosimilar versions are in development but have not yet received FDA approval.

DrugPatentWatch.com tracks these expiration